Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Key Takeaways A new blood test can diagnose Alzheimer’s disease and track its progressionThe test looks for tau proteins that ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...

为解决痴呆诊断生物标志物受种族差异和检测方法影响，且缺乏中国人群相关系统研究的问题，研究人员开展了 “评估六种血浆生物标志物对阿尔茨海默病（AD）和其他神经退行性痴呆的诊断性能” 的研究。结果发现 p-tau 217 诊断 AD 最有效，多种 p-tau 在鉴别诊断中表现良好。该研究为 AD 诊断提供了新依据。